Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (20494)	5/11/1998 7:14:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

I would be inclined to believe Robinson as well, but SRGN was a very poorly managed company and I don't know why LGND wants the whole thing. As I remember, the drug had extremely nasty side effects, far different from LGND's drugs. Furthermore the market for the CTCL indication is quite small. For these reasons, I can see the price of SRGN rising while LGND could fall a bit but will probably hold since it is not fully valued at current prices. However, Robinson must know what he's doing.